Clinical Trial Update: KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating pembrolizumab in combination with MK-1084 in KRAS G12C-mutant non-small cell lung cancer. The study is currently recruiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• MK-1084
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Malignant Neoplasm | Phase 2 | Status: RECRUITING